The disease characteristics that were expectedly prognostic of poor long-term outcomes (earlier relapse and death) included ELN risk category, a diagnosis of secondary (versus de novo) AML, and the presence of a mutation in the known poor-prognosis genes TP53, RUNX1, or FLT3 (Table 2). This evidence concerns the gene TP53 and acute myeloid leukemia.